{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06526793",
            "orgStudyIdInfo": {
                "id": "D7404C00001"
            },
            "organization": {
                "fullName": "AstraZeneca",
                "class": "INDUSTRY"
            },
            "briefTitle": "AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL",
            "officialTitle": "A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "as-monotherapy-in-participants-with-relapsed-refractory-r-r-b-cell-nhl"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-10-28",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-02-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-05-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-03",
            "studyFirstSubmitQcDate": "2024-07-24",
            "studyFirstPostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AstraZeneca",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.",
            "detailedDescription": "This is a modular, Phase II, multicenter, single-arm, open-label study to evaluate the efficacy and safety of AZD0486 monotherapy administered as an intravenous (IV) infusion in participants with relapsed or refractory B-NHL. The purpose of this study is to determine the efficacy and safety of AZD0486 administered at the RP2D in adults 18 to 80 years of age with relapsed or refractory B-NHL."
        },
        "conditionsModule": {
            "conditions": [
                "B-cell Non-Hodgkin Lymphoma",
                "Follicular Lymphoma (FL)",
                "Diffuse Large B-Cell Lymphoma (DLBCL)"
            ],
            "keywords": [
                "AZD0486",
                "Follicular Lymphoma (FL)",
                "Diffuse Large B-Cell Lymphoma (DLBCL)",
                "Non-Hodgkin lymphoma (NHL)",
                "Relapsed/Refractory"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "The trial will assess AZD0486 monotherapy given by IV infusion. Module 1 will evaluate the efficacy and safety of AZD0486 monotherapy at the recommended Phase 2 dose (RP2D), in participants 18 to 80 years of age, with relapsed or refractory (R/R) follicular lymphoma (FL) who have received \u2265 2 prior therapies. Module 2 will evaluate the efficacy and safety of AZD0486 monotherapy at the RP2D for participants 18 to 80 years of age with (R/R) diffuse large B-cell lymphoma (DLBCL).",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 240,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Module 1: AZD0486 Monotherapy in Participants with Relapsed or Refractory Follicular Lymphoma",
                    "type": "EXPERIMENTAL",
                    "description": "In Module 1, the efficacy and safety of AZD0486 at the RP2D will be evaluated in R/R FL. AZD0486 will be administered as intravenous infusion.",
                    "interventionNames": [
                        "Drug: AZD0486"
                    ]
                },
                {
                    "label": "Module 2: AZD0486 Monotherapy in Participants with Relapsed or Refractory DLBCL",
                    "type": "EXPERIMENTAL",
                    "description": "In Module 2, the efficacy and safety of AZD0486 at the RP2D will be evaluated in R/R DLBCL. AZD0486 will be administered as intravenous infusion.",
                    "interventionNames": [
                        "Drug: AZD0486"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "AZD0486",
                    "description": "Investigational Product administered via intravenous infusion.",
                    "armGroupLabels": [
                        "Module 1: AZD0486 Monotherapy in Participants with Relapsed or Refractory Follicular Lymphoma",
                        "Module 2: AZD0486 Monotherapy in Participants with Relapsed or Refractory DLBCL"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "Overall response rate (ORR), defined as the proportion of participants achieving either a PR or CR based on Lugano 2014 response criteria for non-Hodgkin Lymphoma, as determined by central review",
                    "timeFrame": "Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to about 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to about 12 months."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration of response (DoR)",
                    "description": "Defined as the time from the date of first documented response until date of documented progression by Lugano 2014 response criteria as determined by central review or death due to any cause.",
                    "timeFrame": "To be assessed up to approximately 5 years."
                },
                {
                    "measure": "Complete response (CR) rate",
                    "description": "Complete response (CR) based on Lugano 2014 Response criteria for non-Hodgkin lymphoma, as determined by central review.",
                    "timeFrame": "To be assessed up through study completion, up to approximately 5 years"
                },
                {
                    "measure": "Complete response (CR) rate",
                    "description": "Complete response (CR) based on Lugano 2014 Response criteria of non-Hodgkin lymphoma, as determined by investigator assessment.",
                    "timeFrame": "To be assessed up through study completion, up to approximately 5 years"
                },
                {
                    "measure": "Overall response rate (ORR)",
                    "description": "Overall response rate (ORR), defined as the proportion of participants achieving either a PR or CR based on Lugano 2014 Response criteria of non-Hodgkin lymphoma, as determined by investigator assessment.",
                    "timeFrame": "Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to about 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to about 12 months."
                },
                {
                    "measure": "Duration of CR (DoCR)",
                    "description": "Defined as the time from achievement of CR to relapse or death due any cause, as assessed by central review",
                    "timeFrame": "To be assessed up to approximately 5 years."
                },
                {
                    "measure": "Time to response (TTR)",
                    "description": "Defined as the time from first dose until first documented objective response, as assessed by central review.",
                    "timeFrame": "From the first dose until the first objective response, up to approximately 5 years."
                },
                {
                    "measure": "Event-free survival (EFS)",
                    "description": "Defined as the time from first dose until disease progression, relapse, or initiation of subsequent systemic anti-lymphoma treatment, or death due to any cause, as assessed by central review.",
                    "timeFrame": "To be assessed up to approximately 5 years"
                },
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "Defined as the time from the date of first dose until documented disease progression based on Lugano 2014 Response Criteria, or death due to any cause.",
                    "timeFrame": "To be assessed up to approximately 5 years."
                },
                {
                    "measure": "Time to next anti-lymphoma (TTNT)",
                    "description": "Defined as time from first dose until the start of subsequent anti-lymphoma therapy.",
                    "timeFrame": "To be assessed up to approximately 5 years."
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "Defined as the time from first dose until the date of death due to any cause.",
                    "timeFrame": "To be assessed up to approximately 5 years."
                },
                {
                    "measure": "Minimal residual disease (MRD)",
                    "description": "MRD-negative CR rate, defined as the proportion of participants who achieved MRD-negativity in plasma by NGS while in CR per the Lugano Response criteria for non-Hogkin lymphoma as determined by central review.",
                    "timeFrame": "To be assessed up through study completion, up to approximately 5 years"
                },
                {
                    "measure": "Change from baseline in EORTC IL233 scales",
                    "description": "To evaluate patient-reported tolerability of AZD0486, including severity of key treatment-related symptoms and overall side-effect burden\n\nEORCT IL233 scales - European Organisation for Research and Treatment of Cancer Il233 scales- this questionnaire is assessing Patient-reported Severity of Treatment-and Disease-related Symptoms, it is a 15-item questionnaire, and each item is rated on a 4-point scale ranging from 1 (not at all) to 4 (very much).",
                    "timeFrame": "To be assessed up through study completion, up to approximately 5 years"
                },
                {
                    "measure": "Change from baseline in IL232 QL2 score",
                    "description": "To evaluate patient-reported impact of disease general quality of life and functioning, while on AZD0486.\n\nEORTC IL232 - European Organisation for Research and Treatment of Cancer IL232- this questionnaire is assessing Patient-reported Severity of Treatment-and Disease-related Function and Quality of Life. This is a 15-item questionnaire, and item 1-13 are rated on a 4-point scale ranging from 1 (not at all) to 4 (very much), item 14-15 are rated on a 7-point scale ranging from 1 (very poor) to 7 (excellent).",
                    "timeFrame": "To be assessed up through study completion, up to approximately 5 years"
                },
                {
                    "measure": "Change from baseline in FACT-LymS scales",
                    "description": "To evaluate patient-reported severity of key disease-related symptoms, as well as the impact of disease on lymphoma-specific concerns, while on AZD0486\n\nFunctional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) FACT-LymS - Lymphoma-specific Subscale from the FACT-Lym Questionnaire is a 15-item questionnaire, and each item is rated on a 5-point scale ranging from 0 (not at all) to 4 (very much).",
                    "timeFrame": "To be assessed up through study completion, up to approximately 5 years"
                },
                {
                    "measure": "Change from baseline in PGI-T scale",
                    "description": "To evaluate patient-reported tolerability of AZD0486, overall side-effect burden.\n\nPGI-T scale - Patient Global Impression of Treatment Tolerability is a 1 item questionnaire rated on a 7-point scale ranging from \"not at all\" to \"very much\"",
                    "timeFrame": "To be assessed up through study completion, up to approximately 5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "1. Key Inclusion Criteria:\n\n   * Aged 18 to 80 years old\n   * Histologically confirmed relapsed refractory FL (Module 1) and DLBCL (Module 2) after at least 2 prior lines of therapy\n   * ECOG performance status 0 to 2\n   * Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy\n   * FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as \\> 1.5 cm in its longest dimension), or extranodal lesion (defined as \\> 1.0 cm in its longest dimension)\n   * Adequate hematological function: ANC \u2265 1000/mm3, platelets\n\n     * 75,000/mm3, hemoglobin \u2265 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening\n   * Adequate liver function: total bilirubin \\<1.5x ULN, AST/ALT \u2264 3xULN Note: Patients with documented history of Gilbert's Syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible)\n   * Adequate renal function: creatinine clearance (CrCl) of \u2265 45 mL/min\n\n   The above is a summary, other inclusion criteria details may apply.\n2. Key Exclusion Criteria:\n\n   * Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation\n   * Active CNS involvement by B-NHL\n   * Leukemic presentation of B-NHL\n   * History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis\n   * Prior therapy with T-cell engager (TCE) within 8 weeks, CAR T- cell therapy or autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, or prior allogeneic HSCT within 24 weeks of first dose of AZD0486\n   * Requires chronic immunosuppressive therapy\n   * Unresolved non hematological AEs \u2265 Grade 2 from prior therapies; history of \u2265 Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy\n   * History of major cardiac abnormalities.\n   * If female, participant must not be pregnant or breastfeeding.\n\nThe above is a summary, other exclusion criteria details may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AstraZeneca Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-877-240-9479",
                    "email": "information.center@astrazeneca.com"
                }
            ],
            "locations": [
                {
                    "facility": "Research Site",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Des Moines",
                    "state": "Iowa",
                    "zip": "50314",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.60054,
                        "lon": -93.60911
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Overland Park",
                    "state": "Kansas",
                    "zip": "66204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.98223,
                        "lon": -94.67079
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "New Brunswick",
                    "state": "New Jersey",
                    "zip": "08901",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.48622,
                        "lon": -74.45182
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Charlotte",
                    "state": "North Carolina",
                    "zip": "28203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.22709,
                        "lon": -80.84313
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Heidelberg",
                    "zip": "3084",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.75,
                        "lon": 145.06667
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Kogarah",
                    "zip": "NSW 2217",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.98333,
                        "lon": 151.11667
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Macquarie University",
                    "zip": "2109",
                    "country": "Australia"
                },
                {
                    "facility": "Research Site",
                    "city": "Nedlands",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Ottawa",
                    "state": "Ontario",
                    "zip": "K1H 8L6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.41117,
                        "lon": -75.69812
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Berlin",
                    "zip": "10967",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 52.52437,
                        "lon": 13.41053
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Chemnitz",
                    "zip": "09116",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.8357,
                        "lon": 12.92922
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Essen",
                    "zip": "45122",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.45657,
                        "lon": 7.01228
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Wuerzburg",
                    "zip": "97080",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 49.79391,
                        "lon": 9.95121
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Chiba-shi",
                    "zip": "260-8717",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.6,
                        "lon": 140.11667
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Kashiwa",
                    "zip": "277-8577",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.86224,
                        "lon": 139.97732
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Koto-ku",
                    "zip": "135-8550",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.66667,
                        "lon": 139.81718
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Kumamoto-shi",
                    "zip": "860-0008",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 32.80589,
                        "lon": 130.69182
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Niigata-shi",
                    "zip": "951-8520",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 37.88637,
                        "lon": 139.00589
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Okayama-shi",
                    "zip": "700-8558",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.65,
                        "lon": 133.93333
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Osaka-shi",
                    "zip": "541-8567",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.69374,
                        "lon": 135.50218
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Yokohama-shi",
                    "zip": "241-8515",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.43333,
                        "lon": 139.65
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Barcelona",
                    "zip": "8035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Pozuelo de Alarcon",
                    "zip": "28223",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.43293,
                        "lon": -3.81338
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Kaohsiung City",
                    "zip": "833401",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 22.61626,
                        "lon": 120.31333
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Kaohsiung",
                    "zip": "80756",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 22.61626,
                        "lon": 120.31333
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Taichung",
                    "zip": "404",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 24.1469,
                        "lon": 120.6839
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Taichung",
                    "zip": "40705",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 24.1469,
                        "lon": 120.6839
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Tainan City",
                    "zip": "70403",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 22.99083,
                        "lon": 120.21333
                    }
                },
                {
                    "facility": "Research Site",
                    "city": "Taipei City",
                    "zip": "106",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",
            "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements: thttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008224",
                    "term": "Lymphoma, Follicular"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                },
                {
                    "id": "D000016403",
                    "term": "Lymphoma, Large B-Cell, Diffuse"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18831",
                    "name": "Lymphoma, Large B-Cell, Diffuse",
                    "asFound": "Diffuse Large B-cell Lymphoma (DLBCL)",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11221",
                    "name": "Lymphoma, Follicular",
                    "asFound": "Follicular lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-Cell Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1866",
                    "name": "Diffuse Large B-Cell Lymphoma",
                    "asFound": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2361",
                    "name": "Follicular Lymphoma",
                    "asFound": "Follicular lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}